Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This is a phase I/II study of ceritinib and trametinib in Stage IIIB or IV anaplastic
lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). The Phase I portion will
investigate the safety and tolerability of the combination of ceritinib and trametinib in ALK
or ROS-1 rearranged NSCLC. The Phase II portion will investigate the clinical efficiency of
the combination of ceritinib and trametinib in 3 single arm cohorts: ALKi (ALK inhibitor)
naïve patients; post-crizotinib progressed disease (PD) patients; and PD second line ALK
tyrosine kinase inhibitor (TKI) patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Novartis Pharmaceuticals University of California, Davis University of California, Irvine University of California, Los Angeles University of California, San Diego